T2D: No evidence to suggest increased fracture risk with DPP-4i, GLP-1 RA, and SGLT-2i (of 11) Pediatric News , 31 Aug 2022 Key clinical point: Dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and sodium…